Wire · founder news, decoded · opportunities
HoneyNaps Receives U.S. FDA 510(k) Clearance for SOMNUM V3.0 for AI-Based Sleep ...
HoneyNaps' SOMNUM V3.0 AI software for sleep apnea diagnosis has received FDA 510(k) clearance, automatically classifying obstructive, central, and mixed sleep apnea subtypes with 97%+ accuracy. The clearance expands the company's regulatory footprint in clinical sleep diagnostics and signals a pathway for future digital biomarker approvals.
This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.
The Wire takeaway
You can now sell AI diagnostic software directly into sleep labs without proving equivalence to a predicate device—HoneyNaps has cracked the FDA pathway, and the 97% accuracy bar is now the market entry requirement for your competitors in this segment. The next move is selling to hospital systems that already have polysomnography infrastructure but can't hire enough technicians to score the data.
Read the full story at us.acrofan.com →
Topics: Digital Health · fda-510k · sleep-apnea · clinical-ai · medical-devices · diagnostics